Excellent
Mostly Aligned
Patient Risk:
Low
Summary
Most statements in the AI-generated response are consistent with the provided FDA label excerpts (indication limited to adult GD1 with CYP2D6 metabolizer status; mechanism as substrate reduction via inhibition of glucosylceramide synthase; oral administration; dosing and selection based on CYP2D6; interaction-driven dosing considerations; avoidance of grapefruit is label-consistent though not explicitly claimed). Minor issues: generalizations about ERT switching/combination and enzyme-deficiency description are not directly supported by the excerpts.
Category Scores
Accurate Statements
Eliglustat tartrate (Cerdelga) is used to treat adults with Gaucher disease type 1.
Section 1 Indications and Usage: indicated for long-term treatment of adult patients with Gaucher disease type 1 (GD1) (with CYP2D6 metabolizer status).
Eliglustat is an oral therapy.
Section 11 Description indicates oral capsules; also Section 12 Clinical Pharmacology discusses oral bioavailability.
Eliglustat helps reduce glucosylceramide buildup by slowing the production of the material that accumulates.
Section 12.1 Mechanism of Action: inhibitor of glucosylceramide synthase (substrate reduction therapy) reduces production of GL-1 and alleviates accumulation.
Eliglustat acts by inhibiting pathways that lead to glucosylceramide synthesis.
Section 12.1 Mechanism of Action: specific inhibitor of glucosylceramide synthase (reducing GL-1/GL-1 production).
The key practical issue for combining eliglustat with other Gaucher disease treatments is drug–drug interactions and the suitability of the patient’s metabolic profile for eliglustat dosing.
Sections 2.1 and 2.3 (CYP2D6-based selection/dosing and dose frequency adjustments with CYP2D6 or CYP3A inhibitors) and Section 7.1 (inhibitors/inducers affecting eliglustat concentrations and risk of arrhythmias).
Eliglustat eligibility depends on patient factors such as metabolism.
Sections 1 and 2.1: indications and patient selection based on CYP2D6 metabolizer status.
Unsupported Statements
Gaucher disease type 1 is a genetic condition in which glucosylceramide builds up due to deficient activity of the enzyme glucocerebrosidase.
The provided label excerpts do not state the cause/pathophysiology of GD1 (e.g., glucocerebrosidase deficiency).
Enzyme replacement therapies supply the missing enzyme directly.
Not supported or stated within the provided CERDELGA label excerpts.
Eliglustat can be combined with other Gaucher disease treatments depending on the patient's situation and the prescriber's plan.
The excerpts include guidance about switching from enzyme replacement therapy (ERT) 24 hours after the last dose, but do not support a general statement that eliglustat may be combined with other Gaucher treatments.
Clinical studies show eliglustat can reduce the disease-causing substrate.
The provided label excerpt for clinical studies is limited to statistically significant improvements in endpoints versus placebo; the specific claim about reducing the disease-causing substrate is not explicitly stated in the clinical studies excerpt (though mechanism supports substrate reduction).
Clinical studies show eliglustat can improve clinical measures compared with baseline.
The clinical studies excerpt provided mentions improvements vs placebo; it does not explicitly state improvements vs baseline.
Contradictions
Low
AI Statement
Eliglustat can be combined with other Gaucher disease treatments depending on the patient's situation and the prescriber's plan.
Label Reference
Not directly contradicted by provided excerpts, but it is broader than what is supported (label text provided supports switching after last ERT dose rather than general combination).
Important Omissions
Indication is restricted to adults with GD1 who are CYP2D6 extensive/intermediate/poor metabolizers as detected by an FDA-cleared test; the AI statements did not mention CYP2D6 metabolizer status/FDA-cleared testing requirement when stating the indication.
Importance:
Moderate
Contraindication specifics (CYP2D6 metabolizer status-related contraindication due to risk of cardiac arrhythmias from prolongation of PR/QTc/QRS) were not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response mostly describes mechanism and general indication. Main gaps are failure to specify CYP2D6-based selection/testing and not covering key cardiac-arrhythmia contraindication/warnings; these are material label elements, but the response does not provide dosing or high-risk misuse instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Indication description omitted key label restriction (adult GD1 with CYP2D6 metabolizer status determined by an FDA-cleared test) and combination language is broader than supported by provided excerpts.
Suggested Improvement
State the label-restricted indication including CYP2D6 metabolizer status/FDA-cleared testing, avoid general claims of combining with other Gaucher treatments (use label-supported switching timing from ERT if relevant), and include key cardiac contraindication/warning context when discussing suitability.